Invuity, Inc.

No Longer Reporting

The company has not filed an annual or quarterly report since its Q2 FY2018 10-Q, filed Aug 3, 2018. Its latest SEC filing is a SC 13G/A from Feb 14, 2019.

The sections below describe the company as of the FY2017 annual report.

What Did They Do?

Sells illuminated surgical devices and advanced energy tools to hospitals and surgeons for open and minimal-access procedures.

How Did They Make Money?

Hospitals and medical centers buy Invuity's devices through direct representatives and independent agents; it is paid when the products ship.

FY2017 revenue

Who Were Their Customers?

Hospitals and medical centers buy mainly through Invuity's direct sales representatives, with independent agents also selling the devices; Invuity also sells to medical-device manufacturers.

Did Revenues Turn Into Profits?

No. It lost $39.9M in FY2017.

Operating income, FY2017

−89% of revenue

▼ −9% (Loss) vs FY2016 (−$38.7M, −119%)

Net income, FY2017

−101% of revenue

▼ −2% (Loss) vs FY2016 (−$40.6M, −125%)

Free cash flow, FY2017

−100% of revenue

▲ +5% (Loss) vs FY2016 (−$37.7M, −116%)

How Were They Changing?

Since the FY2017 annual report

Latest quarter: Q2 FY2018, the three months to Jun 30, 2018

Revenue: ▲ +8%; vs $9.8M in Q2 FY2017
Net income: ▼ −14% (Loss); vs −$10.4M in Q2 FY2017

Oct 23, 2018 Stryker completed its acquisition of Invuity Invuity became a wholly owned Stryker subsidiary, and each qualifying share was converted into the right to receive cash.
Sep 11, 2018 Invuity agreed to a cash acquisition by Stryker Stryker agreed to offer $7.40 per share, with Invuity to become a wholly owned subsidiary after the tender offer.
Aug 2, 2018 Invuity issued revenue and disposable-sales guidance For 2018, Invuity expected revenue to exceed $46 million and disposable revenue to grow in excess of 25%.
Mar 6, 2018 Philip Sawyer resigned as CEO; Scott Flora became interim CEO

Grew. Revenue grew 88% in 2 years, from $21M in FY2015 to $39.6M in FY2017, about 37% a year.

Comments